Article

Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes

2025-07-12

Abstract excerpt

<h4>ABSTRACT</h4> BCL-2 has been implicated in prostate cancer (PCa) progression and development of castration-resistant disease (CRPC). However, it remains unclear how the BCL-2- and AR-expressing PCa cell populations evolve across the PCa continuum, how AR molecularly regulates BCL-2 and whether BCL-2 represents a common therapeutic target in heterogeneous CRPC. Importantly, BCL-2 inhibitors have yet to be appr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f49d1ec8-43ea-5766-97cd-fa97c37fd616
DOI: 10.1101/2025.07.08.663739

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypesDOI 10.1101/2025.07.08.663739Read

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responsesSemantic proximity Read

Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistanceSemantic proximity Read

BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticitySemantic proximity Read

Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancerSemantic proximity Read

Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor SignalingSemantic proximity Read

Molecular decoupling of lineage identity and morphology in aggressive variant prostate cancerSemantic proximity Read

PHENOTYPIC CHARACTERIZATION OF TWO NOVEL CELL LINE MODELS OF CASTRATION RESISTANT PROSTATE CANCERSemantic proximity Read

[Metastatic castration-resistant prostate cancer-emerging trends in therapy].Semantic proximity Read

Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate CancerSemantic proximity Read

Understanding the development of enzalutamide resistance based on a functional single-cell approachSemantic proximity Read

Development and prevalence of castration-resistant prostate cancer subtypesSemantic proximity Read

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read